Edwards Letting German Centers Stock-Up On Sapien 3 Ahead Of Patent Ruling
As its dispute with Boston Scientific over transcatheter aortic valve replacement technology patents rumbles on, Edwards Lifesciences is offering German interventionalists the option to buy six-months' worth of its Sapien 3 inventory in anticipation of a potential disruption to the supply flow.
You may also be interested in...
Among the medtech companies who have released their first-quarter 2017 sales and earnings, Johnson & Johnson and Merit Medical Systems reported progress in their long-term plans to reshape their medical device businesses, while Abbott and Zimmer Biomet received some bad news in the quarter. Smith & Nephew shows signs of a turnaround, and perennial "winner" Edwards Lifesciences provided updates on some important developments in their flagship transcatheter valve business.
The US Patent & Trademark Office has found three grounds on which to review four claims in a Boston Scientific TAVR patent being challenged by Edwards Lifesciences. The companies have seen mixed recent verdicts in European bodies on related patent disputes.
The worldwide voluntary removal comes in response to reports that the pin that connects the valve to the delivery system sometimes releases prematurely, most likely due to excess tension created during manufacturing.